IL4, interleukin 4, 3565

N. diseases: 996; N. variants: 23
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0004096
Disease: Asthma
Asthma
0.600 Biomarker disease BEFREE Dupilumab blocks the shared receptor component for IL-4 and IL-13, key drivers of type 2 inflammation, including IgE-mediated allergic inflammation in asthma. 31521831 2020
CUI: C0004096
Disease: Asthma
Asthma
0.600 Biomarker disease BEFREE The glucocorticoid-insensitive hyperrresponsiveness in isolated human airways induced by IL-13 and IL-4 provides further evidence that the IL-4Rα pathway should be targeted as a new strategy for treatment of airway hyperresponsiveness in asthma. 31805312 2020
CUI: C0011615
Disease: Dermatitis, Atopic
Dermatitis, Atopic
0.600 Biomarker disease BEFREE Dupilumab (monoclonal antibody inhibiting IL-4/IL-13 signalling) is approved for use in adolescents aged ≥ 12 years with inadequately controlled moderate-to-severe atopic dermatitis (AD). 31595499 2020
CUI: C0011615
Disease: Dermatitis, Atopic
Dermatitis, Atopic
0.600 Biomarker disease BEFREE The multifaceted roles of IL-4 and IL-13 in allergic disease development make IL-4Rα an attractive target for treatment strategies, and a neutralizing monoclonal antibody which antagonizes the effects of both IL-4 and IL-13 by blocking the interaction site found in the IL-4 receptor subunit α (IL-4Rα) has been successfully used to treat patients with moderate-to-severe AD. 31596502 2020
CUI: C0011615
Disease: Dermatitis, Atopic
Dermatitis, Atopic
0.600 Biomarker disease BEFREE HLJDE significantly reduced the clinical symptoms in the AD-like mice by inhibiting eosinophil and mast cell infiltration, suppressing the production of Th2-associated cytokine (IL-4) and pro-inflammatory cytokines (TNF-α). 31678637 2020
CUI: C0004096
Disease: Asthma
Asthma
0.600 Biomarker disease BEFREE Patients with asthma in whom the mucus score was high had raised Feno (P = .03) and IL-4 (P = .02) values. 30910637 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 Biomarker disease BEFREE Asthma is a chronic inflammatory airway disease associated with type 2 cytokines interleukin-4 (IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus overproduction, bronchial hyperresponsiveness (BHR), and immunogloubulin E (IgE) synthesis. 30995510 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 AlteredExpression disease BEFREE Additionally, it promoted the occurrence and development of asthma by influencing the expression levels of IL-7 and various relevant inflammatory factors (such as IL-4 and IL-8) and changing the equilibrium between Treg and Th17 cells. 30713661 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 Biomarker disease BEFREE The results indicated that IL-5 may involve in the pathologic process of asthma-like IL-4, and an inflammatory reaction may still exist in the airway during the remission stage of asthma. 30536454 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 Biomarker disease BEFREE We observed differential methylation across multiple genes for all three phenotypes, including genes implicated previously in innate immunity (DICER1), eosinophilic esophagitis and sinusitis (SIGLEC8), the atopic march (AP5B1) and asthma (EPX, IL4, IL5RA, PRG2, SIGLEC8, CLU). 30876376 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 AlteredExpression disease BEFREE RESULTS The levels of serum IgE and IgG in BLA- or Dex- treated mice were significantly reduced compared to those in the asthma (AS) group (P<0.01), whereas the levels of cytokines IL-4, TNF-α, and MCP-1 were significantly decreased (P<0.01). 30828084 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 AlteredExpression disease BEFREE The levels of IL-4, IgE, PLA<sub>2</sub>, and TP significantly reduced in groups treated with all concentrations of RA compared to asthma group (P<0.001 for all cases). 29983238 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 Biomarker disease BEFREE The mechanism of MSC therapy in asthma seems to be regulating the balance of Th1 cytokine and Th2 cytokines (IFN-γ: Hedges's g = 4.779 ± 1.408 with 95% CI: 1.099-2.725, P < 0.001; IL-4: Hedges's g = -10.781 ± 1.062 with 95% CI: -12.863 ∼ -8.699, P < 0.001; IL-5: Hedges's g = -10.537 ± 1.269 with 95% CI: -13.025 ∼ -8.050, P < 0.001; IL-13: Hedges's g = -6.773 ± 0.788 with 95% CI: -8.318 ∼ -5.229, P < 0.001). 30496803 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 AlteredExpression disease BEFREE Correlation between the pathogenesis of bronchial asthma and serum expressions of IL-4, IL-12, IL-37 and 25-(OH)D. 31184089 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 GeneticVariation disease BEFREE Aerosol Inhalation-mediated Delivery of an Adeno-associated Virus 5-expressed Antagonistic Interleukin-4 Mutant Ameliorates Experimental Murine Asthma. 31678897 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 Biomarker disease BEFREE Dupilumab (a monoclonal antibody blocking the shared receptor component for IL-4 and IL-13) is approved for inadequately controlled moderate-to-severe AD and for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma. 31066001 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 Biomarker disease BEFREE Interleukin-4(IL-4), an anti-inflammatory cytokine, plays significant role in pathogenesis of various diseases such as asthma, tumors, and HIV infections. 30391589 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 AlteredExpression disease BEFREE Asthma children in the observation group exhibited higher levels of interleukin-4 (IL-4), IL-17, and IL-33 than those of the control group (p<0.05). 31539147 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 Biomarker disease BEFREE IL-4 and IL-13 are key cytokines in driving type 2 inflammation, a dominant and largely eosinophilic inflammatory pathway in asthma. 31728838 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 Biomarker disease BEFREE Pathway cross-talk analysis highlights that signaling pathways mediated by IL-4/13 and transcription factor HIF-1α and FOXA1 play crucial roles in the pathogenesis of asthma. 31430856 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 Biomarker disease BEFREE Discovered DMRs annotated to genes implicated in allergic asthma, Th2 activation and eosinophilia (EPX, IL4, IL13) and genes previously associated with asthma and IgE in EWAS of blood (ACOT7, SLC25A25). 31300640 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 Biomarker disease BEFREE PM<sub>2.5</sub> exposure and cold stress exacerbates asthma in mice by increasing histone acetylation in IL-4 gene promoter in CD4<sup>+</sup> T cells. 31520700 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 GeneticVariation disease BEFREE The IL-4 -590C/T and Arg130Gln locus gene polymorphisms are associated with the asthma susceptibility and increased serum total IgE in Uygur children in Xinjiang. 30680016 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 GeneticVariation disease BEFREE These findings coupled with the known insensitivity of CD8<sup>+</sup> T cells to corticosteroids suggests that activation of the IL-4-HIF-1α-IL-13 axis might play a role in the development of steroid-refractory asthma. 30660639 2019
CUI: C0004096
Disease: Asthma
Asthma
0.600 GeneticVariation disease BEFREE The characteristic features of allergic asthma, including airway hyperreactivity, histopathology, cytokine levels (IL-4, -5, -13, -17, and INF-γ), T regulatory (Treg) lymphocytes (Foxp3+CD4+CD25+), and T effector (Teff) lymphocytes (Foxp3-CD25+CD4+) in bronchoalveolar lavage fluid (BALF), and downstream proteins of mTORC1/2 signaling pathway were examined. 30873032 2019